Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim L Jansen

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
Arthritis Research & Therapy|May 23, 2015
Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trialSofie H M Manders, Wietske Kievit, Eddy Adang, et al.
Seminars in Arthritis and Rheumatism|June 12, 2026
The OMERACT core domain sets for calcium pyrophosphate deposition diseaseNicola Dalbeth, Yiling Zhang, Owen Hensey, et al.
Plos One|January 26, 2016
The Toll-Like Receptor 4 (TLR4) Variant rs2149356 and Risk of Gout in European and Polynesian Sample SetsHumaira Rasheed, Cushla McKinney, Lisa K Stamp, et al.
Rheumatology (Oxford, England)|January 31, 2020
Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locusFaseeh Zaidi, Ravi K Narang, Amanda Phipps-Green, et al.
Plos One|December 24, 2010
Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcomeMarieke J H Coenen, Christian Enevold, Pilar Barrera, et al.
Arthritis Care & Research|July 11, 2017
Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of DiseaseMarjan Ghiti Moghadam, Peter M Ten Klooster, Harald E Vonkeman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 12, 2016
Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled TrialMarjan Ghiti Moghadam, Harald E Vonkeman, Peter M Ten Klooster, et al.
BMC Immunology|November 20, 2014
The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseasesJaap Ten Oever, Matthijs Kox, Frank L van de Veerdonk, et al.
BMC Rheumatology|June 22, 2019
Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatmentMarjan Ghiti Moghadam, Femke B G Lamers-Karnebeek, Harald E Vonkeman, et al.
Plos One|May 24, 2018
Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatmentMarjan Ghiti Moghadam, Femke B G Lamers-Karnebeek, Harald E Vonkeman, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Arthritis Research & Therapy|May 23, 2015
Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trialSofie H M Manders, Wietske Kievit, Eddy Adang, et al.
Seminars in Arthritis and Rheumatism|June 12, 2026
The OMERACT core domain sets for calcium pyrophosphate deposition diseaseNicola Dalbeth, Yiling Zhang, Owen Hensey, et al.
Plos One|January 26, 2016
The Toll-Like Receptor 4 (TLR4) Variant rs2149356 and Risk of Gout in European and Polynesian Sample SetsHumaira Rasheed, Cushla McKinney, Lisa K Stamp, et al.
Rheumatology (Oxford, England)|January 31, 2020
Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locusFaseeh Zaidi, Ravi K Narang, Amanda Phipps-Green, et al.
Plos One|December 24, 2010
Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcomeMarieke J H Coenen, Christian Enevold, Pilar Barrera, et al.
Arthritis Care & Research|July 11, 2017
Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of DiseaseMarjan Ghiti Moghadam, Peter M Ten Klooster, Harald E Vonkeman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 12, 2016
Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled TrialMarjan Ghiti Moghadam, Harald E Vonkeman, Peter M Ten Klooster, et al.
BMC Immunology|November 20, 2014
The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseasesJaap Ten Oever, Matthijs Kox, Frank L van de Veerdonk, et al.
BMC Rheumatology|June 22, 2019
Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatmentMarjan Ghiti Moghadam, Femke B G Lamers-Karnebeek, Harald E Vonkeman, et al.
Plos One|May 24, 2018
Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatmentMarjan Ghiti Moghadam, Femke B G Lamers-Karnebeek, Harald E Vonkeman, et al.
Pageof 9